Edoxaban for Venous Thromboembolism Treatment—The New Kid on The Block for Latin America. A Practical Guide

Edoxaban, a direct factor Xa inhibitor (FXa), is the fourth direct oral anticoagulant (DOAC) approved for clinical use in the treatment of venous thromboembolism (VTE) in Latin America, following global approvals for this indication. Edoxaban features some particular characteristics when compared to...

Descripción completa

Detalles Bibliográficos
Autores principales: Ramacciotti, Eduardo, Aguiar, Valéria Cristina Resende, Júnior, Valter Castelli, Casella, Ivan Benaducce, Zerati, Antonio Eduardo, Fareed, Jawed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6714848/
https://www.ncbi.nlm.nih.gov/pubmed/30486661
http://dx.doi.org/10.1177/1076029618812955

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6714848/
https://www.ncbi.nlm.nih.gov/pubmed/30486661
http://dx.doi.org/10.1177/1076029618812955

Ejemplares similares